- Home
- ATOS vs YSXT Comparison
ATOS vs YSXT Comparison
Compare ATOS & YSXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- YSXT
- Stock Information
- Founded
- ATOS 2009
- YSXT 2011
- Country
- ATOS United States
- YSXT China
- Employees
- ATOS N/A
- YSXT N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- YSXT Automotive Aftermarket
- Sector
- ATOS Health Care
- YSXT Consumer Discretionary
- Exchange
- ATOS Nasdaq
- YSXT Nasdaq
- Market Cap
- ATOS 96.8M
- YSXT 79.2M
- IPO Year
- ATOS 2012
- YSXT 2024
- Fundamental
- Price
- ATOS $0.89
- YSXT $4.66
- Analyst Decision
- ATOS Strong Buy
- YSXT
- Analyst Count
- ATOS 3
- YSXT 0
- Target Price
- ATOS $7.13
- YSXT N/A
- AVG Volume (30 Days)
- ATOS 611.2K
- YSXT 57.5K
- Earning Date
- ATOS 05-13-2025
- YSXT 02-24-2025
- Dividend Yield
- ATOS N/A
- YSXT N/A
- EPS Growth
- ATOS N/A
- YSXT N/A
- EPS
- ATOS N/A
- YSXT 0.18
- Revenue
- ATOS N/A
- YSXT $66,143,276.00
- Revenue This Year
- ATOS N/A
- YSXT N/A
- Revenue Next Year
- ATOS N/A
- YSXT N/A
- P/E Ratio
- ATOS N/A
- YSXT $24.73
- Revenue Growth
- ATOS N/A
- YSXT 21.23
- 52 Week Low
- ATOS $0.55
- YSXT $2.06
- 52 Week High
- ATOS $1.74
- YSXT $6.27
- Technical
- Relative Strength Index (RSI)
- ATOS 64.44
- YSXT N/A
- Support Level
- ATOS $0.78
- YSXT N/A
- Resistance Level
- ATOS $0.92
- YSXT N/A
- Average True Range (ATR)
- ATOS 0.06
- YSXT 0.00
- MACD
- ATOS 0.01
- YSXT 0.00
- Stochastic Oscillator
- ATOS 81.82
- YSXT 0.00
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About YSXT YSX Tech. Co. Ltd Class A Ordinary Shares
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services and Software Development and Information Technology Services. Key revenue is generated from Auto Insurance Aftermarket Value-added Services segment which include four types value added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services and vehicle maintenance and other value-added services.